Therefore, a combination therapy of PD-1 therapy and IL-10 neutralization makes resistant tumors sensitive to PD-1 therapy in a mouse ovarian tumor model (Lamichhane et al., 2017). The gene discussed is PDCD1; the disease is ovarian neoplasm.